TRIP12 and cancer: RNF168 expression and signaling is deregulated in tumors and cancer cell lines by mechanisms that include increased mRNA expression, downregulation of TRIP12 and UBR5 proteases, as well as reduced expression of enzymes that de-ubiquitinate ub-H2AX (21,32–34).